文献速递肝肾功能剂量调整药物相互作用

多拉韦林的临床药效学、药代动力学及药物相互作用特征

Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
PubMed 文献 · Clin Pharmacokinet · 2019-01-01

多拉韦林是新型非核苷类逆转录酶抑制剂(NNRTI),III期试验显示其疗效不劣于依非韦伦和达芦那韦/利托那韦方案,且神经精神不良反应更少。本综述评估了其药效学、药代动力学、药物相互作用及耐药特征,提示每日一次给药药代动力学良好,主要经CYP3A代谢,与强CYP3A诱导剂禁忌。

要点

  • 多拉韦林每日一次给药,消除半衰期约15小时,达稳态需7天。
  • 强CYP3A诱导剂(如利福平)禁忌合用;中度诱导剂利福布汀需加量至100mg每日两次。
  • 单药片剂在肾功能不全时无需调整剂量,但固定剂量复方片在肌酐清除率<50 mL/min时不推荐。

核心结论

  • 多拉韦林对野生型HIV-1及常见NNRTI变异株有强效抗病毒活性,疗效不劣于依非韦伦和达芦那韦/利托那韦方案。
  • 多拉韦林药代动力学不受性别、年龄、种族或肝功能损害显著影响,药物相互作用潜力低。
  • 强CYP3A诱导剂(如利福平)因显著降低暴露而禁忌合用,中度诱导剂利福布汀需调整剂量。

研究设计与样本

  • 本文为临床综述,评估多拉韦林的药效学、药代动力学、药物相互作用及耐药特征。
  • 综述基于健康志愿者和HIV感染者的研究数据,以及III期临床试验结果。

主要发现

  • 多拉韦林消除半衰期约15小时,血药浓度达峰时间中位数1-4小时,达稳态时间7天。
  • 与依非韦伦相比,多拉韦林神经精神不良反应更少。
  • 多拉韦林对部分常见临床相关NNRTI耐药突变具有体外活性,初治队列中基线耐药流行率低。

关键数值与推荐

  • 单药片剂在肾功能不全时无需调整剂量;固定剂量复方片(多拉韦林/拉米夫定/富马酸替诺福韦二吡呋酯)在肌酐清除率<50 mL/min时不推荐使用。
  • 强CYP3A诱导剂(如利福平)禁忌与多拉韦林合用;中度CYP3A诱导剂(如利福布汀)可合用但多拉韦林需增至100 mg每日两次。
  • 强CYP3A抑制剂可显著增加多拉韦林暴露,但被认为无临床相关性。

临床怎么用

  • 临床使用多拉韦林时应评估合并用药,避免与强CYP3A诱导剂合用,与利福布汀合用时需调整剂量。
  • 肾功能不全患者使用单药片剂无需调整剂量,但使用固定剂量复方片需注意肌酐清除率<50 mL/min时不推荐。
  • 多拉韦林可作为初治HIV-1感染患者的治疗选择之一,尤其关注神经精神不良反应风险较高者。

局限性

  • 关于多拉韦林在经治患者和/或传播性NNRTI耐药患者中的疗效数据仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) that has demonstrated good efficacy, tolerability, and safety for the treatment of patients with human immunodeficiency virus (HIV)-1 infection in phase III clinical trials. Doravirine achieved non-inferiority when compared with efavirenz- and darunavir/ritonavir-based regimens. Fewer adverse effects, including neuropsychiatric effects were observed with doravirine compared with efavirenz. Key pharmacodynamic and pharmacokinetic characteristics as well as drug-drug interactions and the resistance profile were assessed in this clinical review. Doravirine is a pyridinone NNRTI with potent antiviral activity against wild-type HIV-1 virus and common NNRTI variants. Studies in healthy volunteers and HIV-infected individuals have shown that doravirine has a favorable pharmacokinetic profile for once-daily dosing, with an elimination half-life of around 15 h, median time to maximum plasma concentrations of 1-4 h, and time to steady-state concentration of 7 days. The pharmacokinetics of doravirine are not greatly influenced by sex, age, race, or hepatic impairment. Although no dose adjustment is required for doravirine in renal impairment when given as a single tablet, the fixed-dose combination tablet of doravirine/lamivudine/tenofovir disoproxil fumarate is not recommended in patients with a creatinine clearance of < 50 mL/min. Doravirine has a low potential for drug-drug interactions and does not impact on the pharmacokinetics of other drugs. However, it is metabolized via cytochrome P450 (CYP) 3A enzymes and is thus susceptible to interactions with CYP3A inhibitors and inducers. Strong CYP3A inhibitors can significantly increase doravirine exposure; however, this is not considered to be clinically relevant. Conversely, strong CYP3A inducers, such as rifampin, are contraindicated with doravirine owing to a significant reduction in exposure with potential for impaired virological efficacy. Moderate CYP3A inducers, such as rifabutin, may be co-administered if the doravirine dose is increased to 100 mg twice daily. Doravirine has a unique resistance profile and has demonstrated in vitro activity against some of the most common, clinically relevant NNRTI-resistant mutations. Prevalence of baseline NNRTI resistance to doravirine appears to be low in treatment-naïve cohorts. Further data on the efficacy of doravirine in patients with previous treatment experience and/or transmitted NNRTI resistance are required to further inform its place in the current armamentarium of drugs for the treatment of HIV infection.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Boyle A, Hodge D, Marzolini C, et al. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine. Clin Pharmacokinet. 2019. PMID: 31388941. doi:10.1007/s40262-019-00806-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。